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Abstract
Due to their remarkable selectivity and specificity for cancer biomarkers, immunoconjugates
have emerged as extremely promising vectors for the delivery of diagnostic radioisotopes and
fluorophores to malignant tissues. Paradoxically, however, these tools for precision medicine are
synthesized in a remarkably imprecise way. Indeed, the vast majority of immunoconjugates are
created via the random conjugation of bifunctional probes (e.g., DOTA-NCS) to amino acids
within the antibody (e.g., lysines). Yet antibodies have multiple copies of these residues
throughout their macromolecular structure, making control over the location of the conjugation
reaction impossible. This lack of site specificity can lead to the formation of poorly defined,
heterogeneous immunoconjugates with suboptimal in vivo behavior. Over the past decade,
interest in the synthesis and development of site-specifically labeled immunoconjugates—both
antibody-drug conjugates as well as constructs for in vivo imaging—has increased dramatically,
and a number of reports have suggested that these better defined, more homogeneous
constructs exhibit improved performance in vivo compared to their randomly modified cousins. In
this two-part review, we seek to provide an overview of the various methods that have been
developed to create site-specifically modified immunoconjugates for positron emission
tomography, single photon emission computed tomography, and fluorescence imaging. We will
begin with an introduction to the structure of antibodies and antibody fragments. This is followed
by the core of the work: sections detailing the four different approaches to site-specific
modification strategies based on cysteine residues, glycans, peptide tags, and unnatural amino
acids. These discussions will be divided into two installments: cysteine residues and glycans will
be detailed in Part 1 of the review, while peptide tags and unnatural amino acids will be
addressed in Part 2. Ultimately, we sincerely hope that this review fosters interest and
enthusiasm for site-specific immunoconjugates within the nuclear medicine and molecular
imaging communities.
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Over the last three decades, medical imaging has revolu-
tionized cancer care, providing clinicians with the means to
noninvasively acquire anatomical, functional, and biological
information about tumors. Due to their remarkable affinity
and specificity for cancer biomarkers, antibodies—as well as
an ever-growing array of antibody fragments—have played
an increasingly important role in this field (Fig. 1) [1, 2].
Indeed, antibody conjugates bearing a wide range of
reporters—ranging from Zr-89 for positron emission tomog-
raphy (PET) to near-infrared fluorophores for optical
imaging (OI)—have been successfully developed and
translated to the clinic [3, 4].
Yet paradoxically, these agents designed to enable
Bprecision medicine^ are synthesized in a rather imprecise
manner. At present, the vast majority of bioconjugation
techniques rely on reactions between bifunctional probes and
amino acids, typically lysines (Fig. 2a, b) [5–7]. For
example, in the case of Zr-89-labeled antibodies for PET
imaging, an isothiocyanate-bearing derivative of the Zr-89
chelator desferrioxamine (DFO-NCS; Fig. 3) is conjugated
randomly to lysines in the immunoglobulin [6]. However,
antibodies possess varying numbers of these residues
distributed throughout their macromolecular structure. Thus,
controlling the molecular location of these conjugation
reactions and the number of conjugations per antibody is
impossible.
These random bioconjugation approaches produce
immunoconjugates that are poorly defined and heteroge-
neous on three different levels [8–10]. First, a single
conjugation reaction using these methods will produce a
product with a range of degrees of labeling. For example, the
total population of an immunoconjugate with an average
loading of 3 chelators/monoclonal antibody (mAb) will
include subpopulations with degrees of labeling ranging
from 0 to well above 3. Second, even immunoconjugates
that possess identical degrees of labeling are likely to be
regioisomers. If, for example, we assume an antibody has 40
available lysines, an immunoconjugate with a degree of
labeling of 2 chelators/mAb is actually a mixture of up to
780 different regioisomers, while an immunoconjugate with
a degree of labeling of 3 chelators/mAb is actually a mixture
of over 10,000 different regioisomers! And third, random
conjugation strategies present batch-to-batch reproducibility
issues. Even if two batches of an immunoconjugate possess
the same degree of labeling, it is extremely unlikely that
these two batches are composed of the exact same mixture
of regioisomers.
This heterogeneity should not be dismissed as an
academic issue. Each regioisomer has a unique set of
chemical, biological, and pharmacological traits. An anti-
body with a single fluorophore attached to a lysine in the
CH3 region, for example, will likely exhibit in vivo
pharmacokinetics different from that of an antibody bearing
five fluorophores attached to lysines in the VH and CH1
domains. Furthermore, without the ability to control the
precise location of the conjugation reactions, cargoes may
become appended to the antigen-binding domains of the
antibody, thus impairing the immunoreactivity of the
conjugate [11]. Taken together, these issues can have
adverse effects on the in vivo performance of
immunoconjugates, resulting in suboptimal pharmacokinet-
ics, decreased accumulation in target tissues, and increased
uptake in healthy tissues. There are logistical drawbacks to
random bioconjugation methods as well. In the absent of
precise control over the modification process, every new
immunoconjugate must undergo extensive optimization, a
process that can be costly, time-consuming, and tedious.
In response to these problems, the last decade has played
witness to a great deal of research into the development of
methodologies for the site-specific modification of antibod-
ies [8, 12–16]. On the most basic level, the key to any site-
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specific bioconjugation strategy is selectivity. A variant of
the cargo molecule—whether a chelator, fluorophore, drug,
or prosthetic group—must be designed to react
chemoselectively with a specific site or sites in the structure
of the antibody. Effective site-specific bioconjugation
strategies have been developed using a wide range of
pathways to achieve chemoselectivity, including
bioorthogonal organic transformations, click chemistry, and
enzymatic reactions [17–22]. Regardless of the specifics,
however, the end result in every case is straightforward: the
creat ion of bet ter def ined, more homogeneous
immunoconjugates.
Practically speaking, these site-specific modification
strategies offer a number of important advantages over
traditional random modification methods. First, site-specific
approaches reproducibly yield better defined and more
homogeneous immunoconjugates, simultaneously eliminat-
ing the problems of heterogeneity and irreproducibility
created by random approaches. Second, because site-
specific procedures enable the precise control over the
molecular location of the conjugation reaction, these
methods prevent the inadvertent attachment of cargoes to
the antigen-binding domains of the antibody. Third, it is
almost certain that regulatory agencies would look more
favorably on well-defined, homogeneous immunoconjugates
compared to the complex, heterogeneous mixtures of
constructs created using random conjugation strategies.
Finally, and perhaps most importantly, a number of
intriguing reports have found that site-specifically modified
immunoconjugates exhibit superior in vivo behavior to their
traditionally synthesized cousins, boasting more favorable
pharmacokinetics, higher uptake in target tissues, and lower
background accumulation in healthy tissues [14, 23–27].
In this two-part review, it is our goal to provide an
overview of the various methods that have been developed
to create site-specifically modified immunoconjugates for
PET, single photon emission computed tomography
(SPECT), and fluorescence imaging. Furthermore, due to
the advent of antibody fragments as smaller, more
pharmacokinetically rapid alternatives to full-length IgGs,
we have decided to include immunoconjugates based on
these constructs as well [28, 29]. Given the tremendous
amount of work to cover, we have divided this review into
two parts. In Part 1, we will begin with an introduction to the
structure of antibodies and antibody fragments, followed by
detailed discussions of the site-specific modification strate-
gies based on cysteine residues and glycans. In Part 2, we
will shift our focus to site-specific bioconjugation ap-
proaches based on peptide tags and unnatural and nonca-
nonical amino acids. In Part 2, we will also offer a broad
overview of the advantages and disadvantages of the various
approaches to conjugation as well as some rumination on the
direction of the field as a whole. Importantly, there are a
number of cases in which a given site-specific modification
strategy has been used in the creation of an antibody-drug
conjugates (ADCs) but has not yet been employed to create
an immunoconjugate for imaging. In these cases, we have
chosen to discuss the approach in question—if only
briefly—in order to increase the breadth of this work and
encourage the application of these methods to imaging
agents. For readers specifically interested in the construction
of ADCs, we recommend a few recent and extremely well-
written reviews [8, 14, 16]. In addition, we have found a
small number of reports detailing the creation of site-
specifically labeled antibodies for radioimmunotherapy;
given that the development of agents for nuclear imaging
and targeted radiotherapy often go hand in hand, we have
included these examples as well. Finally, we would also like
to issue a small caveat. The development of site-specific
antibody modification strategies is a rapidly growing field.
We have tried to cover as many of the different approaches
as we could find in the literature. However, it is all but
Fig. 1 Detailed structural schematic of a full-length IgG as well as an assortment of antibody fragments.
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certain that we have missed at least one report, most likely




Discovered in the late nineteenth century as toxin-
neutralizing agents in the blood of animals infected with
diphtheria, antibodies are globular proteins produced by the
immune system, hence the term Bimmunoglobulin^ [30]. As
seen in electron micrographs, antibodies are Y-shaped
molecules with a bifurcated end joined to a stalk by a
flexible hinge region (Fig. 1) [31]. The forked end consists
of the antigen-binding fragments—i.e., the Fab region—that
define the specificity of the antibody for its antigen target,
while the stalk—i.e., the Fc region—interacts with receptors
on immune effector cells. Structurally speaking, immuno-
globulins are heterodimeric proteins composed of two
~55 kDa polypeptide chains dubbed the Bheavy^ chains
(H) and two ~25 kDa polypeptide chains dubbed the Blight^
chains (L). Based on the specific composition of the heavy
chains, immunoglobulins can be categorized into a number
Fig. 2 The basic chemical reactions underpinning the bioconjugation strategies discussed in this work.
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of different isotypes, including IgA, IgM, IgD, IgE, and IgG.
In contrast, there are only two types of light chains: kappa
(κ) and lambda (λ). For the sake of simplicity, we will limit
this discussion of antibody structure to IgG molecules, the
most abundant isotype in antiserum.
The heavy and light chains are composed of a number of
segmented domains, which are broadly categorized as the
constant (C) and variable (V) domains. Each domain has
110–130 amino acid residues, averaging a molecular weight
of 12.5 kDa [32]. While the heavy chain of a typical IgG has
three C domains (CH1, CH2, CH3) and one V domain (VH),
the light chain is made up of one V domain (VL) and one C
domain (CL). Taken together, there are a total of 12
individual domains per IgG molecule. These domains are
organized further into a three-dimensional structure which is
primarily held together by noncovalent hydrophobic inter-
actions, hydrogen bonds, and van der Waals forces.
However, covalent disulfide bonds play a very important
Fig. 3 Selected chelators and cargoes used in the site-specifically labeled immunoconjugates discussed in this work.
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role in the structure of IgGs as well. Typically, IgGs possess
16 disulfide bonds formed between 32 cysteine residues.
Four of these linkages are interchain disulfide bonds: two in
the flexible hinge region and two that connect the constant
domains within the Fab region: CH1 with CL. The remaining
12 are intrachain disulfide bonds, with one linkage per
domain. Considering the topic at hand, it is important to note
that the abundance of hydrophobic interactions between the
various domains allows for the inter- and intrachain
disulfides to be partially reduced or even substituted without
compromising the structural integrity of the antibody [33].
The key to the extraordinary specificity of antibodies lies in
the V domains of the immunoglobulin. The V domains of
the Fab region are composed of four framework regions
interspersed with three hypervariable complementarity de-
termining regions: CDR1, CDR2, and CDR3 [34, 35]. The
framework regions principally contribute to the stability and
interdomain interactions between the heavy and light chain
domains. The unique antigen-binding pocket, or paratope, is
created by the three-dimensional organization of the CDRs
of both the L and H chains and ultimately confers diversity
and specificity to an antibody for its target antigen [10].
The posttranslational glycosylation of antibodies adds an
additional structural element and has important implications
for their function as well [36]. Antibodies are glycoproteins,
and different isotypes are characterized by different degrees
of glycosylation. IgGs, for example, are known to have an
overall 3 % carbohydrate content, with a conserved
glycosylation site at N297 on both CH2 domains within the
Fc region. Glycans attached to this residue comprise a
complex biantennary heptasaccharide unit formed by D-
galactose (Gal), N-acetyl-D-galactosamine (GalNAc), N-
acetylglucosamine (GlcNAc), L-fucose (Fuc), and D-man-
nose (Man). In addition to contributing to the proper folding
and solubility of immunoglobulins, glycans impact the
downstream activation of immune effector functions by
virtue of their interaction with the complementary Fc
receptors on immune effector cells [37].
Antibody Fragments
As early as 1950, experiments by Porter et al. found that
antibodies can be digested with enzymes to produce two
independent Fab fragments and an Fc fragment [38–40].
Not long after, it was found that peptic digestion of
antibodies yielded two products: a dimeric F(ab′)2 and an
Fc fragment [41]. Purification of these moieties revealed
that the isolated Fab and F(ab′)2 units were capable of
binding to the target antigen of the parent antibody with
specificity and selectivity, albeit with different valencies.
This work has led to the emergence of antibody engineer-
ing and the production of a variety of antibody fragments
based on the smallest, completely functional monovalent
antigen-binding unit of an IgG: the single-chain variable
fragment (scFv) (~28 kDa) [28, 42].
From an imaging point of view, antibody fragments offer
a number of enticing traits, including (a) rapid clearance
from systemic circulation, (b) better extravasation and tumor
penetration than full-length antibodies, and (c) immunologic
inertness due to the absence of the Fc region. Furthermore,
the recombinant technology used to produce these fragments
provides an opportunity to introduce genetic modifications
to improve target avidity and binding valence as well as to
facilitate bioconjugation [28]. Indeed, beyond F(ab′)2, Fab,
and scFv fragments, a variety of other engineered constructs
have been created, including diabodies (Db), cys-diabodies
(cysDb), minibodies (Mb), single-domain antibodies (sdAb),
and scFv-Fc fusion constructs (Fig. 1) [28, 42–44].
Immunoconjugates based on these fragments have demon-
strated significant promise in preclinical imaging investiga-
tions; admittedly, however, the clinical potential of
engineered fragments has yet to be fully realized.
Cysteine Residues
Cysteine residues and their thiol functional groups have long
been attractive targets for the selective modification of
peptides and proteins [45]. Much like the lysines targeted
in traditional bioconjugation approaches, cysteine residues
occur naturally within antibodies; importantly, however,
antibodies contain fewer cysteines than lysines, and these
cysteine residues occur only at specific and well-defined
locations within the immunoglobulin. From a bioconjugation
standpoint, the most enticing trait of cysteines is their ability
to undergo highly selective ligations via Michael additions
and alkylations. The most commonly employed thiol-
reactive moiety is the maleimide, which undergoes a
Michael addition with the sulfhydryl group to form a
maleimidyl-thioether bond (Fig. 2c). However, many have
argued that this linkage is less than ideal for bioconjugation
due its instability to hydrolysis and propensity for exchange
reactions with endogenous, thiol-bearing proteins. As a
result, significant effort has been dedicated to the develop-
ment of more efficient thiol-reactive constructs (Fig. 2d–h)
[22, 46, 47]. As we have discussed, full-length IgGs
typically contain 32 cysteine residues that combine to form
12 intrachain and 4 interchain disulfide bridges. Naturally,
these numbers go down when considering antibody frag-
ments: Fab fragments, for example, possess four intrachain
and one interchain disulfide bridges. Interchain disulfides are
the more attractive natural conjugation targets, both because
they are more easily reduced than their intrachain counter-
parts and because of their position far from the antigen-
binding domains. However, some laboratories have sought
to move past the modification of naturally occurring
disulfides, instead using genetic engineering to incorporate
free cysteine residues into immunoglobulins with the express
purpose of creating conjugation sites (Fig. 4). In this section,
we will discuss approaches that have been developed to site-
specifically modify full-length IgGs and smaller fragments
using both native and engineered cysteine residues.
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Native Cysteines
Without a doubt, the simplest thiol-based site-specific
modifications are those made to native cysteines. For
example, in 2002, Sato et al. created an anti-tenascin-C
(TNC) Fab′ via the digestion of an anti-TNC IgG with
pepsin and the subsequent reduction of the disulfides in the
hinge region [48]. The free sulfhydryl groups were then
conjugated to a maleimide-bearing variant of ethylenedi-
aminetetraacetic acid (EDTA), and the unreacted thiols
were quenched with iodoacetamide, yielding a conjugate
with a degree of labeling of 1.4 EDTA/Fab′ (Fig. 3). After
radiolabeling the Fab′-EDTA construct with In-111, the
radioimmunoconjugate was successfully employed for in
vivo imaging in a murine model of myocarditis. Using a
very similar strategy, another laboratory created a CA125-
targeting Fab′ fragment from the mouse IgG B43 [49]. In
this case, however, instead of a maleimide-bearing con-
struct, the researchers employed a bifunctional variant of
1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid
(TETA) (Fig. 3) with a pendant bromoacetamide group
(BAT) for conjugation to the free, hinge region thiols. The
TETA-modified Fab′ was then radiolabeled with Cu-67,
a n d i t w a s d e t e rm i n e d t h a t t h e c omp l e t e d
radioimmunoconjugate possessed immunoreactivity com-
parable to the unmodified Fab′. However, no reports of in
vivo experimentation with the [67Cu]TETA-Fab′ construct
could be found in the initial report or any follow-up
publications. In a third example, over 20 years ago, Slinkin
et al. created an anti-carcinoembryonic antigen (CEA) Fab′
via the digestion of a full-length IgG with pepsin and the
reduction of the hinge region disulfides of the F(ab′)2
intermediate with mercaptoethylamine (MEA) [50]. The
authors then Bactivated^ the Fab′ using Ellman’s reagent
(DTNB), isolated the reactive Fab′-TNB, and reacted the
fragment with two different diethylenetriaminepentaacetic
acid (DTPA)-bearing polylysine constructs: one bearing a
maleimide to create a thioether linkage and another
Fig. 4 Table of site-specific bioconjugation strategies based on the modification of cysteine residues.
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containing a (pyridyldithio)proprionate functionality
geared toward the production of a reducible disulfide
bridge. After radiolabeling the immunoconjugates with In-
111, a biodistribution study was carried out in mice
bearing LS174T human colorectal carcinoma xenografts.
Interestingly, while the thioether-linked radiotracer was
shown to target the tumor efficiently, the disulfide-bridged
compound resulted in high levels of kidney uptake and
poor tumor targeting, likely the result of the in vivo
cleavage of the S-S linkage between the radiometal and the
antibody.
While the methods described above work very well for
the modification of Fab′ fragments, they are not appropriate
for intact antibodies. After all, IgGs contain four interchain
disulfide bridges, and their nonspecific reduction can create
as many as eight different free cysteines [51]. Needless to
say, the modification of an antibody bearing eight different
conjugation sites hardly qualifies as site-specific. In order to
circumvent this issue, a number of laboratories have
employed strategies geared toward the selective reduction
of disulfide linkages [52]. In an excellent example, Sun et al.
explored these possibilities during their efforts to site-
specifically conjugate a maleimide-bearing variant of
monomethyl auristatin E (MMAE) to an anti-CD30 mAb
[53]. The authors report that the reducing agents dithiothre-
itol (DTT) and tris(2-carboxyethyl)phosphine (TCEP) can
preferentially reduce the disulfide bonds bridging the heavy
and light chains when used in small amounts. Interestingly,
it was also found that the same disulfide bridges can be
preferentially oxidized when the fully reduced IgG is
subjected to reoxidation. Armed with this information, the
authors were able to create a variety of ADCs and test their
performance in vitro and in vivo. It is important to note that
the isomeric homogeneity of these constructs ranged from
60 to 90 %, values that are impressive yet certainly leave
room for improvement.
Most of the strategies discussed above are accompanied
by the loss of interchain disulfide bridges. While this is
generally tolerated, it is far from ideal, as these interchain
links confer stability to the antibodies. Two different groups
in the UK have circumvented this issue by employing
bifunctional constructs that are capable of attaching a cargo
to the immunoglobulin while also establishing a covalent
interchain link. In one case, this was achieved through the
use o f a po lye thy l eneg lyco l (PEG) -mod i f i ed
dibromomaleimide moiety capable of performing two
separate nucleophilic substitutions with the cysteines that
had once formed an interchain disulfide bond (Fig. 2g) [54].
In the other example, the authors employed a PEG-
containing bisulfone group that is likewise capable of
covalently relinking the erstwhile disulfide thiols [55].
Finally, Schumacher et al. have also used divalent
maleimides—specifically dibromomaleimides and
dithiophenolmaleimides—to functionalize antibody frag-
ments while retaining a covalent crosslink where a disulfide
once existed (Fig. 2g–h) [56].
Engineered Cysteines
An alternative to the use of native cysteine residues lies in
the genetic incorporation of engineered cysteines as bespoke
modification sites. This approach comes with both advan-
tages and disadvantages. On the plus side, it allows the
native cysteine residues of the immunoglobulin to remain
intact, thereby eliminating the possibility of any harm to the
antibody. In addition, the use of engineered thiol sites allows
the researcher to precisely tailor both the location and
number of conjugation sites. On the other hand, it has been
shown that free, unpaired cysteine residues can spontane-
ously oxidize to form undesired disulfide bridges, leading to
aggregation and structural modifications [57, 58]. Moreover,
the location of the incorporation site must be chosen very
carefully in order to eliminate the risk of interfering with the
antigen-binding domains. In response to these issues,
Junutula et al. developed the phage ELISA for selection of
reactive thiols (PHESELECTOR) biochemical assay, a
procedure that provides information on the influence that
the site of the introduced cysteine has on antigen-binding
affinity as well as the ability to covalently modify the thiol
in question [59]. Finally, the genetic engineering of
immunoglobulins undeniably adds complexity and expense
to the synthetic process as well. This is particularly true for
full-length IgGs and F(ab′)2 fragments. However, even the
most basic syntheses of diabodies, minibodies, or scFv
require genetic engineering. Thus, in these cases, the genetic
incorporation of additional cysteine residues can be achieved
with relatively little added effort.
In the last few years, a number of laboratories have
employed genetic engineering to create site-specifically
modified immunoconjugates based on antibody fragments.
In 2014, for example, Anna Wu’s laboratory reported the
development of anti-activated leukocyte cell adhesion
molecule (ALCAM) cysDb [60]. After reduction with
TCEP, these constructs were conjugated to a maleimide-
bearing bifunctional 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) to yield constructs with
exactly two chelators per diabody (Fig. 3). For the sake of
comparison, the cysDbs were also randomly modified using
DOTA-NHS. Both immunoconjugates were successfully
radiolabeled with 64Cu and used for PET imaging in mice
bearing ALCAM-positive and ALCAM-negative xenografts.
While both Cu-64-labeled diabodies effectively discriminat-
ed between the two tumor types, the site-specifically labeled
[64Cu]DOTA-cysDb exhibited higher tumoral uptake and
more favorable tumor-to-background activity concentration
ratios than its randomly labeled cousin. In addition, the site-
specific labeling of the cysDb also seemed to exert a
significant influence on the pharmacokinetic profile of the
radioimmunoconjugate, increasing kidney uptake and de-
creasing liver retention compared to the randomly labeled
construct.
Other laboratories have synthesized a range of site-
specifically radiolabeled fragments via reactions with C-
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terminal cysteines, including an anti-TNC [111In]DTPA-
scFv, an anti-human epidermal growth factor receptor 2
(HER2) [111In]DTPA-sdAb, an anti-MUC1 [111In]DOTA-
di-scFv, and an anti-CEA [64Cu]DO3A-GLGK-cysDb
(Fig. 3) [61–64]. In a small variation on this approach, Li
et al. employed DO3A-PEGn constructs (n=12, 24, and 48)
bearing a vinyl sulfone moiety to site-specifically modify an
anti-TAG-72 diabody with a C-terminal cysteine (Fig. 3 and
5a) [65]. After radiolabeling these conjugates with Cu-64,
PET imaging was performed using mice bearing LS174T
xenografts, and the authors found that while all of the
diabodies proved able to target the tumor, the background
activity levels in the blood and kidneys were highly
dependent on the length of the PEG chain. Conjugations
with C-terminal cysteines have also been used for the
creation of immunoconjugates for fluorescence imaging.
For example, Sirk et al. used maleimide-bearing variants of
AlexaFluor® 488, phycoerythrin, and allophycocyanin to
create anti-HER2 and anti-CD20 cysDbs for in vitro
fluorescence imaging (Fig. 3) [66]. More recently, a group
in the Netherlands reported the development of a series of
HER2-targeting nanobodies site-specifically conjugated to
the near-infrared fluorophore IRDye 800CW through C-
terminal cysteine residues (Fig. 3) [67]. In vivo fluorescence
imaging experiments using mice bearing HER2-positive
SKBR3 breast cancer xenografts revealed that the site-
specifically labeled nanobodies yielded higher tumor-to-
background intensity ratios than a construct that had been
randomly modified through lysine residues. Moreover, these
probes were shown to possess significant promise for
intraoperative imaging during the surgical resection of
tumors.
In their efforts to reduce the retention of radioisotopes in
the kidneys—a frequent stumbling block for radiolabeled
antibody fragments—the laboratories of Wu and Shively
provided an excellent comparative case study on the various
thiol-reactive conjugation strategies [68]. In this work, the
authors incorporated a GLGK tetrapeptide linker between an
anti-CEA cysDb and a DO3A chelator that is designed to be
cleaved specifically by the carboxypeptidase activity of
kidney brush border enzymes (Fig. 3). In theory, this
modification could facilitate the specific cleavage of the
tetrapeptide upon the inevitable uptake of the fragment in the
kidney, thereby facilitating the rapid elimination of the
radiometal-chelate complex even though the diabody re-
mains trapped in the kidney. To this end, GLGK peptides
were functionalized on the N-terminus with a DO3A
chelator and on the ε amino group of the lysine residue
with three different thiol-reactive moieties: a maleimide, a
bromoacetyl group, and a vinylsulfone group. These DO3A-
peptide constructs were then site-specifically attached to the
C-terminal cysteine of the diabody, producing conjugates
with degrees of labeling ranging from 0.8 to 1.3 chelators/
cysDb. These constructs—along with a nonsite-specifically
labeled variant—were labeled with In-111, and
biodistribution experiments were performed in mice bearing
LS174T colon cancer xenografts. As expected, high activity
concentration levels were observed in the kidneys for the
randomly modified conjugate [111In]DOTA-cysDb but also,
somewhat surpr i s ing ly , the bromoace ty l -based
[111In]DO3A-GLGK-cysDb construct. In contrast, dramati-
cally reduced kidney uptake was observed for the conjugates
created using the maleimide and vinylsulfone approaches.
This clearly underscores that the conjugation strategy may
have as much of a role in influencing biodistribution as the
addition of the cleavable peptide.
Fig. 5 a Serial PET images of site-specifically labeled
[64Cu]DOTA-PEG24-AVP04-50 (top) and [
64Cu]DOTA-PEG48-
AVP04-50 (bottom) in athymic nude mice bearing LS174T
xenografts. The labels in red, green, yellow, and turquoise
illustrate the %ID/g values in the heart, liver, kidney, and
tumor, respectively. Figure adapted and reprinted with the
permission of Li et al. Copyright 2011 American Chemical
Society [65]. b PET images of four different variants of
[89Zr]DFO-thio-trastuzumab in mice bearing BT474 xeno-
grafts. In two of the radioimmunoconjugates, the chelator
was attached using nonsite-specific conjugation methods
(Bz-SCN and N-Suc), while in the other two constructs,
bioconjugation was achieved using thiol-reactive variants of
DFO (Chx-Mal and Ac). Figure adapted and reprinted with the
permission of Tinianow et al. Copyright 2010 Elsevier
Publishing Group [17].
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The incorporation of cysteines via genetic engineering
has also been applied to full-length IgGs to produce what
has often been dubbed BthiomAbs.^ Stimmel et al., for
example, mutated position 442 in the CH3 domain of an IgG
to replace a serine residue with a cysteine [69]. The mutant
IgG was then partially reduced with MEA to free the
engineered thiol while leaving the native disulfides un-
touched. This construct was then conjugated to a
bromoacetamide-bearing variant of the TMT chelator to
yield a final construct with between one to two chelators/
mAb and an immunoreactivity nearly identical to that of the
unmodified antibody (Fig. 3). Much more recently, a team
from Genentech developed a genetically engineered variant
of trastuzumab with cysteine residues incorporated in the
heavy chain [17]. This thiomAb was reduced with an excess
of DTT and then partially reoxidized with dehydroascorbic
acid in order to selectively prepare the engineered thiols for
modification with variants of the Zr-89 chelator
desferrioxamine (DFO; Fig. 3) bearing thiol-reactive
bromoacetyl, iodoacetyl, or maleimide groups (Fig. 5b).
These trastuzumab-DFO immunoconjugates were found to
have approximately 1.8 DFO/mAb, were labeled with Zr-89
in high yield and radiochemical purity, and were found to
have immunoreactivities and stabilities comparable to
constructs created using nonsite-specific conjugation meth-
odologies. In a separate study, Boswell et al. developed a
maleimide-bearing tyrosine-DOTA construct as a scaffold
for the site-specific iodination of immunoconjugates. The
tyrosine-DOTA moiety was first labeled with I-125 and
subsequently attached to a HER2-targeting thioMab, with
the ultimate aim of developing residualizing radioiodinated
antibodies for both PET imaging (using I-124) and therapy
(using I-131) [70].
ThiomAbs can also be enzymatically digested to afford
F(ab′)2, Fab′, and Fab fragments bearing engineered cysteine
residues. Using this approach, the same group at Genentech
created a HER2-targeting thioFab [71]. This fragment was
then conjugated to an F-18-labeled PEGylated maleimide
moiety that had been prepared via copper-catalyzed azide-
alkyne click chemistry (Fig. 2i). In order to explore alternate
synthetic strategies, the same radioimmunoconjugate was
also synthesized in a two-step procedure based on the initial
bioconjugation of an alkyne-bearing PEGylated maleimide
followed by the copper-catalyzed ligation of an azide-
containing F-18-labeled synthon. However, the authors
ultimately concluded that the former strategy is preferable,
as it precludes any degradation of the antibody fragment by
the CuI click chemistry catalyst.
All of the cysteine-based modification strategies we have
discussed offer enticing possibilities. The approaches based
on the manipulation of native cysteines are refreshingly
simple and require no genetic engineering, while the
methods employing engineered cysteines offer unprecedent-
ed levels of regiochemical control. However, a major
limitation to all these strategies lies in the suboptimal
biological stability of maleimdyl thioether bonds. Other
thiol-reactive constructs have been used effectively, yet the
maleimide-thiol Michael addition reaction persists as the
standard technology for cysteine-based conjugations. We are
confident, however, that the next few years will witness
increases in the use of more suitable chemical tools for thiol-
based conjugations, such as phenyloxadiazole sulfones,
dibromomaleimides, and dithiophenolmaleimides (Fig. 2g–
h, j) [22, 46, 47].
Glycans
IgGs contain two conserved glycosylation sites—the N297
residues in the CH2 domains of the heavy chains—each
bearing a biantennary, complex-type oligosaccharide chain
(Fig. 6a). These heavy chain glycans have three significant
advantages as a platform for site-specific modification: (1)
the heavy chain CH2 domains lie far from the antigen-
binding regions of the IgG, thus minimizing the risk of
inadvertently impairing the immunoreactivity of the anti-
body; (2) the basic chemistry of sugars differs fundamentally
from that of amino acids, meaning that the glycans can be
manipulated without disturbing the polypeptide chain; and
(3) the biantennary nature of the two oligosaccharide chains
opens the door for at least two and as many as four
conjugation events per antibody.
Oxidation-Based Methods
The oldest methodologies for the site-specific modification
of antibodies rely on the oxidation of the heavy chain
glycans (Fig. 7) [8, 16, 72–74]. It is well known that sugars
can be oxidized using periodate (IO4
−) to create aldehydes
(Fig. 2k). These aldehydes can then react selectively with
nucleophiles—including amines, hydrazide, and aminooxy
groups—to form covalent linkages (Fig. 2l–p). Importantly,
there are two major caveats to these oxidation-based
conjugation methodologies. First, some of the bonds formed
via the reaction of the aldehydes with nucleophiles—for
example, imine linkages—are hydrolytically unstable, and
therefore, a reduction step is required to obtain stable
immunoconjugates. Second, the initial treatment of the
glycans with periodate is not always benign: it is known
that this step may also result in the oxidation of methionine
residues, which may in turn inadvertently affect the ability of
the antibody to bind its antigen [75].
In 1986, Rodwell et al. first applied this method to the
s y n t h e s i s o f s i t e - s p e c i f i c a l l y m o d i f i e d
radioimmunoconjugates [26, 76]. In this work, the major
histocompatibility complex (MHC)-targeting antibody
R9.75 was oxidized using NaIO4, coupled to one of three
moieties bearing a primary amine—an I-125 labeled penta-
peptide ([125I]GYGGR), a DTPA-bearing tripeptide (GYK-
DTPA), or a p-aminoaniline-DTPA—and finally reduced
using sodium cyanoborohydride (Fig. 2l). After
radiolabeling with In-111, the immunoconjugates were
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successfully used to image mice bearing lymphoma xeno-
grafts via scintigraphy. A comparison with nonsite-
specifically modified immunoconjugates illustrated that the
site-specifically labeled radioimmunoconjugates targeted
tumor tissue far more effectively. In more recent years,
other groups have followed similar strategies for the
synthesis of radioiodine-labeled constructs [74]. In addition,
a number of site-specifically modified [111In]DTPA-labeled
radioimmunoconjugates have been made using the chelator
GYK-DTPA, including examples based on the anti-prostate-
specific membrane antigen (PSMA) antibody 7E11-C5, the
anti-carcinoembryonic antibody C46, the breast cancer-
targeting murine IgG 15A8, and the TAG72-targeted
antibody B72.3 (i.e., satumomab) [77–80]. All of these
radioimmunoconjugates have been shown to successfully
target tumor tissue in murine models of cancer, and notably,
[111In]DTPA-satumomab has been used in the clinic in
patients with colorectal cancer [80].
The aldehydes produced by the oxidation of the glycans
can also react with hydrazides to form hydrazone-based
linkages (Fig. 2m). While hydrazones possess greater innate
stability than their imine cousins, hydrazones can also be
reduced via sodium cyanoborohydride to create hydrazine-
based linkages, further increasing their durability [81].
Along these lines, Stalteri et al. oxidized and coupled the
PSMA-targeting antibody 7E11C5.3 with the hydrazine-
bearing chelator CYT-395, radiolabeled the resulting
immunoconjugate with Tc-99m, and were able to effectively
image prostate cancer tumors in patients (Fig. 3) [82, 83].
Using similar methods, Zuberbühler et al. employed
hydrazide-bearing fluorophores to create a fluorescent
immunoconjugate based on the anti-fibronectin antibody
F8 [84]. Another group took a slightly different approach,
mod i fy ing the an t i -CD5 an t ibody T101 wi th
dihydrazinophthalazine (DHZ), a compound bearing two
hydrazides: while one reacted with the aldehyde to site-
specifically modify the antibody, the other was subsequently
employed as part of a coordination scaffold for Tc-99m
(Fig. 2n) [85]. The authors found that the resulting site-
specifically Tc-99m-labeled radioimmunoconjugate proved
more stable than an analogous, traditionally conjugated
variant. More recently, in an effort to develop In-111-
labeled immunoconjugates for Auger electron radiotherapy,
Lu et al. site-specifically conjugated polymers bearing ~30
DTPA each to trastuzumab via oxidation with NaIO4,
reaction with the hydrazide-bearing polymers, and reduction
with NaBH3CN [86]. The resulting constructs were shown
to have approximately 1.2 polymers/mAb and could be
successfully labeled with 111In in high yield and at higher
specific activities than traditional, lysine-conjugated
trastuzumab-DTPA. The authors illustrated that the modifi-
cation of the In-111-labeled radioimmunoconjugate did not
have a deleterious effect on the KD of the antibody for
HER2; however, the polymer-modified antibodies showed
Fig. 6 a The biantennary structure of the heavy chain glycans; the dotted outlines indicate residues that are not always present
in the glycans. b Structures of natural and synthetic monosaccharides.
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significantly increased nonspecific binding to cells that did
not express the target antigen. While a follow-up study
published in 2015 presented some promising in vitro results,
no in vivo data was provided in either report, leaving the
pharmacokinetic influence of the DTPA-laden polymers
unknown for now [87].
A final variation on this theme employs O-alkyl hydrox-
ylamines as the nucleophile in order to form aldehyde oxime
ethers, which are more hydrolytically stable than imine or
hydrazone products and do not require a subsequent
reduction step (Fig. 2o–p) [88]. Kurth and colleagues
applied this strategy to the development of a
radioimmunotherapeutic agent, using an aminooxy-bearing,
I-125-labeled iodophenyl construct and the mAb 35, which
targets the Gold 3 epitope of the carcinoembryonic antigen
[89]. The site-specifically labeled I-125 mAb 35
radioimmunoconjugates were synthesized in high specific
activity and immunoreactivity and were shown to be highly
stable. More importantly, in biodistribution experiments
using mice bearing subcutaneous T380 colorectal cancer
x e n o g r a f t s , t h e s i t e - s p e c i f i c a l l y l a b e l e d
radioimmunoconjugate was found to have higher tumor
Fig. 7 Site-specific bioconjugation strategies based on the modification of glycans.
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retention and lower thyroid uptake than a variant produced
using a nonsite-specific radioiodination method. Unfortu-
nately, however, we were unable to find any in vivo therapy
data using this construct or, perhaps more appropriately, a I-
131-bearing analog. More recently, Bejot et al. followed a
similar route to label trastuzumab with an aminooxy-bearing
variant of DOTA, producing a site-specifically labeled
radioimmunoconjugate with 5.1 ± 0.7 DOTA/mAb, a very
high immunoreactive fraction, and low nonspecific binding
to HER2-negative cells. Subsequent SPECT imaging exper-
iments using mice bearing subcutaneous, bilateral MDA-
MB-361 (HER2-positive) and MDA-MB-231 (HER2-
negative) breast cancer xenografts illustrated that the site-
specifically labeled [111In]DOTA-trastuzumab specifically
targeted the HER2-expressing xenografts but did not offer a
significant improvement over an [111In]DOTA-trastuzumab
construct synthesized using a traditional, nonsite-specific
conjugation method [90].
Glycoengineering Methods
Over the last 15 years, a number of alternative
chemoenzymatic methods for the specific functionalization
of glycoproteins have emerged. Using both natural and
engineered enzymes, it is now possible to introduce carefully
tailored sugars into the glycans to enable chemoselective
modifications. Not surprisingly, this work has been enthu-
siastically applied to the creation of site-specifically labeled
radioimmunoconjugates.
The most well-known enzyme used in these methodolo-
gies is Gal-T1(Y289L), a mutant β-1,4-galactosyltransferase
developed by Qasba and coworkers. This substrate-
permissive galactosyltransferase facilitates the attachment
of modified galactose monomers to N-acetylglucosamine
(GlcNAc) residues in the glycans (Fig. 6b) [91]. Two
modified galactose residues have served as focal points: 2-
acetyl-2-deoxy-galactose (2-keto-Gal) and N-azido-
acetylgalactosamine (GalNAz; Fig. 6b). Each of these
monomers can be used for bioorthogonal conjugations: the
former can be reacted with nucleophiles in a manner similar
to oxidized sugars while the latter is obviously a substrate
for a variety of click chemistry transformations (Fig. 2i).
Both of these unnatural sugars have been successfully
incorporated into antibodies using Gal-T1(Y289L) to dem-
onstrate proof-of-concept and to create fluorescently labeled
antibodies for in vitro imaging applications [92, 93].
The first application of this Gal-T1(Y289L)-based method-
ology for the construction to nuclear imaging agents was
published in 2013 [13]. In this work, Zeglis et al. employed a
three-step modification procedure: (1) the removal of terminal
galactose residues of the glycans using β-1,4-galactosidase, (2)
the attachment of Gal-NAz to the sugar chains using Gal-
T1(Y289L), and (3) the conjugation of chelator-modified
dibenzocyclooctynes to the glycans via the strain-promoted
azide-alkyne click reaction (Figs. 2q and 8). Using this
methodology, the authors created a desferrioxamine (DFO)-
bearing immunoconjugate of the PSMA-targeting antibody
J591 and subsequently labeled this construct with Zr-89.
In vivo PET imaging and biodistribution experiments in mice
bearing subcutaneous PSMA-expressing LNCaP prostate
cancer xenografts suggested that the site-specifically labeled
radioimmunoconjugate produces slightly higher absolute tu-
moral uptake (67.6±5.0 %ID/g at 96 h postinjection) than an
analogous agent produced using a traditional, nonsite-specific
modification strategy (57.5±5.3 %ID/g at 96 h postinjection).
In a subsequent study, the same group used an improved, one-
pot modification strategy to create a series of DFO- and
AlexaFluor® 680-bearing immunoconjugates based on the
huA33 antibody for the multimodal PET/near-infrared fluores-
cence imaging of colorectal cancer (Fig. 9) [18]. In this work,
PET and fluorescence imaging experiments suggested that the
site-specifically modified radioimmunoconjugates exhibited
comparable—if not slightly superior—in vivo behavior com-
pared to variants produced using non-site-specific conjugation
methods.
In an effort to create more homogeneously functionalized
glycans chains, Boons and coworkers have recently devel-
oped a modified chemoenzymatic strategy [94]. In this
strategy, terminal galactose residues are first added to the
glycans using galactosyltransferase (GalT) and uridine
diphosphate (UDP)-galactose. Then, an azide-modified sialic
acid monomer is incorporated into the glycans chain using
sialyltransferase (ST6GalI) and the donor substrate CMP-9-
N3Sia. Finally, strain-promoted azide-alkyne click chemistry
is employed to attach dibenzocyclooctyne (DBCO)-modified
cargoes to the antibody. This glycans remodeling strategy
yielded 3.5 and 4.1 drugs/mAb for the control and anti-
CD22 antibodies, respectively, strongly suggesting quanti-
tative labeling of the termini of the heavy chain glycans.
Using a similar strategy, Zhou et al. sought to increase the
amount of sialic acid in the glycan chains via modification
with GalT and then sialyltransferase (SialT) [12]. These
sialic acid monomers were then specifically oxidized under
mild conditions, and the resulting aldehydes were used to
conjugate aminooxy-bearing variants of MMAE (Fig. 3) and
dolastatin 10 (Dol10; Fig. 3).
A more elegant method for the incorporation of orthog-
onally functionalized sugars into glycoproteins lies in
harnessing the metabolism of cells. This method consists
of enriching the media of cells with modified acetyl-bearing
sugars and relying on the cells themselves to incorporate
these monomers into glycoproteins. In 2014, Rochefort et al.
used this method to prepare an anti-CA19-9 antibody site-
specifically modified with azide groups via the metabolic
incorporation of peracetylated N-azido-acetylmannosamine
[95]. After purification, the azide-modified antibody was
then labeled with a phosphine-bearing fluorophore
(DyLight-650) via the Staudinger ligation, and in vivo
fluorescence imaging was used to show that the
immunoconjugate was specifically taken up in BxPC3
pancreatic adenocarcinoma xenografts (Fig. 2r). The primary
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drawback of this method, however, is the poor incorporation
of functionalized sugars: a fluorophore/mAb ratio of only
1:11 was achieved. Okeley and coworkers used a similar
metabolic engineering approach to incorporate 6-thiofucose
Fig. 8 Schematic of a Gal-T(Y289L)-based site-specific modification procedure.
Fig. 9 a PET and b near-infrared fluorescence images of athymic nude mice bearing SW1222 tumors (white arrows) injected
with either site-specifically labeled or traditionally labeled [89Zr]DFO-huA33-Alexa Fluor® 680. In the PET images, the coronal
slices intersect the center of the tumors. Figure adapted and reprinted with the permission of Zeglis et al. Copyright 2014
American Chemical Society [18].
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site-specifically into the heavy chain glycans of the CD30-
targeting antibody cAC10 and the CD70-targeting antibody
h1F6 (Fig. 6b) [96, 97]. The authors found that 1.2–1.4
thiofucose monomers were incorporated per antibody
and—using a cysteine reduction/reoxidation strategy and a
male imide-bear ing var ian t of MMAE—crea ted
immunoconjugates bearing 1.3 drugs/mAb that proved more
stable to decomposition via retro-Michael addition than an
analogous immunoconjugate in which the interchain
disulfides had been modified.
As the recency of these citations illustrates, the use of
metabolic glycans engineering to create site-specifically
modified antibodies—let alone site-specifically modified
antibodies for imaging applications—remains a very young
field. Thus, in order to maximize the benefits of this
technology, it is crucial that imaging-focused laboratories
continue to investigate the use of existing metabolic
engineering technologies and prove quick to leverage any
new advances in the years to come [96, 97].
Conclusion
In the preceding pages, we have discussed an array of site-
specific bioconjugation strategies that are predicated on two
simple functionalities: cysteine residues and glycans. Of
course, each approach has its own intrinsic advantages and
disadvantages. For example, while the modification of
natural cysteine residues is both modular and straightfor-
ward, it does not offer the same degree of homogeneity and
stoichiometric control as other approaches. Conversely,
conjugation to engineered cysteine residues provides an
exquisite level of stoichiometric and regiochemical control
but requires genetic engineering, which limits its modularity
and broad applicability. Likewise, while the modification of
glycans via bioorthogonal click chemistry is modular, facile,
and straightforward, the usefulness of this approach is
necessarily limited to immunoglobulins with pendant sugar
chains. Setting specifics aside, however, each of these
strategies offers a route to immunoconjugates that are more
homogenous and better defined than constructs created using
traditional bioconjugation techniques. Furthermore, preclin-
ical studies have shown that these site-specifically labeled
immunoconjugates often boast superior in vivo behavior
compared to their randomly constructed cousins. Somewhat
curiously, while the clinical validation of site-specifically
labeled immunoconjugates is of the utmost importance,
work in this area seems to have stalled just short of the
clinic. In our humble opinion, the move from bench to
bedside is the most pressing imperative for the field.
In closing, it is important to note that in this installment
of the review, we have only covered two of the four families
of site-specific modification strategies. In Part 2 of this
work, which will appear in the next issue of the journal, we
will shift gears and discuss bioconjugation approaches based
on peptide tags and unnatural amino acids, methods which
elegantly harness chemoselective ligations and enzymatic
transformations to create site-specifically modified
immunoconjugates.
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